The stock of Alx Oncology Holdings Inc (ALXO) has seen a -14.75% decrease in the past week, with a -6.02% drop in the past month, and a -14.75% decrease in the past quarter. The volatility ratio for the week is 10.30%, and the volatility levels for the past 30 days are at 13.28% for ALXO. The simple moving average for the past 20 days is -4.99% for ALXO’s stock, with a -74.13% simple moving average for the past 200 days.
Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?
Additionally, the 36-month beta value for ALXO is 0.98. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALXO is 34.33M and currently, short sellers hold a 24.45% ratio of that float. The average trading volume of ALXO on January 03, 2025 was 952.05K shares.
ALXO) stock’s latest price update
Alx Oncology Holdings Inc (NASDAQ: ALXO)’s stock price has dropped by -6.59 in relation to previous closing price of 1.67. Nevertheless, the company has seen a loss of -14.75% in its stock price over the last five trading days. globenewswire.com reported 2024-12-18 that SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Jefferies repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Jefferies is $2 based on the research report published on December 19, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $14, previously predicting the price at $10. The rating they have provided for ALXO stocks is “Hold” according to the report published on March 08th, 2024.
Jefferies gave a rating of “Buy” to ALXO, setting the target price at $18 in the report published on December 08th of the previous year.
ALXO Trading at 2.84% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.25% of loss for the given period.
Volatility was left at 13.28%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +0.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.00% upper at present.
During the last 5 trading sessions, ALXO fell by -14.75%, which changed the moving average for the period of 200-days by -85.75% in comparison to the 20-day moving average, which settled at $1.6420. In addition, Alx Oncology Holdings Inc saw -6.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pinto Shelly, who sale 1,426 shares at the price of $1.58 back on Dec 30 ’24. After this action, Pinto Shelly now owns 90,123 shares of Alx Oncology Holdings Inc, valued at $2,253 using the latest closing price.
Pons Jaume, the PRESIDENT & CSO of Alx Oncology Holdings Inc, sale 10,796 shares at $1.58 during a trade that took place back on Dec 30 ’24, which means that Pons Jaume is holding 580,714 shares at $17,060 based on the most recent closing price.
Stock Fundamentals for ALXO
Current profitability levels for the company are sitting at:
- -64.47 for the present operating margin
- 0.74 for the gross margin
The net margin for Alx Oncology Holdings Inc stands at -60.95. The total capital return value is set at -1.04. Equity return is now at value -98.94, with -74.50 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -13.17. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -93.11.
Currently, EBITDA for the company is -158.4 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 30.65. The receivables turnover for the company is 2.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
In conclusion, Alx Oncology Holdings Inc (ALXO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
